Table 4.
Pathways significantly deregulated after EOM-treatment of HEL 12469 cells as identified by Goeman's global test
| ID | KEGG pathway | Ostrava-Bartovice | Ostrava-Poruba | Karvina | Trebon |
|---|---|---|---|---|---|
| Adj. p-value* | |||||
| 980 | Metabolism of xenobiotics by cytochrome P450 | 4.06E-04 | 2.97E-05 | 4.71E-04 | 1.70E-03 |
| 4270 | Vascular smooth muscle contraction | 3.08E-04 | 2.06E-03 | 1.09E-01 | 2.41E-03 |
| 4310 | Wnt signaling pathway | 5.14E-03 | 1.32E-04 | 7.07E-03 | 2.88E-03 |
| 30 | Pentose phosphate pathway | 5.64E-03 | 8.84E-03 | 1.27E-01 | 3.19E-02 |
| 140 | Steroid hormone biosynthesis | 1.03E-02 | 2.58E-03 | 4.29E-03 | 3.37E-02 |
| 2010 | ABC transporters | 1.17E-02 | 1.86E-03 | 3.51E-02 | 4.34E-03 |
| 561 | Glycerolipid metabolism | 1.50E-02 | 2.63E-03 | 4.38E-02 | 5.03E-03 |
| 770 | Pantothenate and CoA biosynthesis | 1.64E-02 | 4.78E-02 | 3.68E-02 | 1.46E-01 |
| 4540 | Gap junction | 1.80E-02 | 3.50E-02 | 8.14E-02 | 3.63E-02 |
| 4350 | TGF-beta signaling pathway | 1.84E-02 | 3.07E-02 | 3.09E-02 | 1.29E-02 |
| 4115 | p53 signaling pathway | 2.39E-02 | 1.70E-01 | 2.74E-01 | 7.77E-02 |
| 520 | Amino sugar and nucleotide sugar metabolism | 2.58E-02 | 6.46E-03 | 1.22E-01 | 9.54E-02 |
| 600 | Sphingolipid metabolism | 2.63E-02 | 2.72E-01 | 8.92E-02 | 3.45E-02 |
| 52 | Galactose metabolism | 2.63E-02 | 1.97E-02 | 1.86E-01 | 7.77E-02 |
| 620 | Pyruvate metabolism | 2.89E-02 | 2.68E-02 | 1.00E+00 | 4.05E-02 |
| 982 | Drug metabolism - cytochrome P450 | 3.01E-02 | 9.84E-05 | 1.49E-03 | 9.04E-02 |
| 480 | Glutathione metabolism | 3.08E-02 | 2.13E-03 | 7.91E-03 | 6.30E-02 |
| 72 | Synthesis and degradation of ketone bodies | 3.83E-02 | 2.10E-01 | 2.74E-01 | 1.00E+00 |
| 4340 | Hedgehog signaling pathway | 5.23E-02 | 2.22E-03 | 5.75E-02 | 4.33E-02 |
| 5217 | Basal cell carcinoma | 5.06E-02 | 5.04E-03 | 4.86E-02 | 5.16E-02 |
| 40 | Pentose and glucuronate interconversions | 6.10E-02 | 5.70E-03 | 1.59E-01 | 6.37E-02 |
| 4142 | Lysosome | 7.53E-02 | 5.78E-03 | 4.30E-01 | 7.05E-02 |
| 565 | Ether lipid metabolism | 5.47E-02 | 1.23E-02 | 1.52E-02 | 1.38E-02 |
| 4614 | Renin-angiotensin system | 5.43E-02 | 1.33E-02 | 1.22E-01 | 6.17E-01 |
| 590 | Arachidonic acid metabolism | 5.71E-02 | 1.97E-02 | 7.05E-02 | 4.70E-02 |
| 4744 | Phototransduction | 1.56E-01 | 2.07E-02 | 4.15E-01 | 2.22E-02 |
| 511 | Other glycan degradation | 1.09E-01 | 2.64E-02 | 5.96E-01 | 7.55E-02 |
| 4610 | Complement and coagulation cascades | 1.15E-01 | 2.85E-02 | 9.83E-01 | 4.56E-01 |
| 5222 | Small cell lung cancer | 1.48E-01 | 3.07E-02 | 4.63E-01 | 7.55E-02 |
| 4612 | Antigen processing and presentation | 4.26E-01 | 3.35E-02 | 5.52E-01 | 2.08E-01 |
| 5140 | Leishmaniasis | 1.18E-01 | 3.58E-02 | 2.20E-01 | 5.18E-02 |
| 4145 | Phagosome | 5.26E-02 | 4.38E-02 | 1.00E+00 | 1.16E-01 |
| 564 | Glycerophospholipid metabolism | 3.80E-01 | 1.08E-01 | 7.85E-01 | 6.10E-03 |
| 4730 | Long-term depression | 2.77E-01 | 4.64E-01 | 1.00E+00 | 7.49E-03 |
KEGG pathways deregulated in all localities are in bold. PM2.5 samples were collected in 4 localities of the Czech Republic, and extractable organic matters (EOMs) were prepared as described in Materials and Methods.
*The procedure of Holm for control of the family-wise error rate [62].